ras peptide-pulsed dendritic cell vaccine

The ras peptide-pulsed dendritic cell vaccine is an autologous cellular immunotherapy designed to stimulate a targeted immune response against tumors harboring RAS mutations. The production process involves isolating peripheral blood mononuclear cells (PBMCs) from a patient, which are then differentiated into dendritic cells ex vivo using cytokines such as sargramostim (GM-CSF) and interleukin-4 (IL-4). These dendritic cells are further matured (often using CD40 ligand) and "pulsed" or loaded with synthetic peptides corresponding to specific oncogenic RAS mutations (most commonly KRAS mutations like G12D, G12V, or G12C) identified in the patient's tumor. When re-administered to the patient, these professional antigen-presenting cells present the mutant RAS epitopes via MHC molecules to T cells, theoretically overcoming the inherent immune tolerance or poor immunogenicity of these intracellular oncoproteins and inducing a cytotoxic T-lymphocyte (CTL) response against RAS-mutated cancer cells.

Other names

mutant ras peptide-pulsed dendritic cell vaccineras peptide-pulsed DC vaccinemutated ras peptide-pulsed autologous dendritic cell vaccine